Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BAA – Large Scale T Cell Epitope Discovery for Priority Pathogens

by Global Biodefense Staff
June 3, 2013

The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the discovery of T cell epitopes that are important in protection of humans from infectious diseases, with a focus on potential bioterrorism agents and other emerging and re-emerging Infectious Diseases.

The primary purpose of this initiative is to establish multiple highly interactive teams to discover such epitopes, with a focus on NIAID Category A, B, and C Priority Pathogens. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation and microbiologists or virologists with expertise in the target pathogens.

This solicitation focuses on the identification and validation of immunodominant and subdominant T cell epitopes, which bind MHC class I, MHC class II, or non-classical MHC/HLA molecules. A companion solicitation for B cell epitopes is also available, B Cell Epitope Discovery and Mechanisms of Antibody Protection, BAA-NIAID-DAIT-NIHAI2012159.

The discovery and validation of novel T cell epitopes will facilitate the design and development of vaccines, improved immune-based therapeutics; and diagnostic tools for the prevention, treatment and detection of such infections, by providing critical information needed to select MHC-peptide or other MHC-ligand complexes that induce T cell activation for the generation and maintenance of protective immunity.

It is anticipated that multiple cost reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about September 1, 2014.

Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2013167.

Tags: BAABioterrorism

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories
Biosecurity

Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories

May 5, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC